AI assistant
Apogee Therapeutics, Inc. — Director's Dealing 2024
Dec 16, 2024
31550_dirs_2024-12-16_b247b8e8-c8c6-4c7a-b99d-7298733be25d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Apogee Therapeutics, Inc. (APGE)
CIK: 0001974640
Period of Report: 2024-12-12
Reporting Person: McKenna Mark C. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-12 | Common Stock | P | 7500 | $49.02 | Acquired | 7500 | Direct |
| 2024-12-12 | Common Stock | P | 12500 | $49.85 | Acquired | 20000 | Direct |
Footnotes
F1: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $48.50 to $49.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.6275 to $50.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range.